Recombinant human endostatin combined with chemotherapy for advanced squamous cell lung cancer: a meta-analysis

Table 4 The meta-analysis of adverse reactions

Adverse reaction	Number of included studies	Heterogeneity		Outcome model	OR	95% CI	p
Adverse reaction	Number of included studies	P	I²	Outcome model	OR	95% CI	p
Gastrointestinal reactions	8 [12,13,14, 16,17,18,19, 24]	0.83	0%	Fixed-effect model	0.86	(0.56,1.30)	0.46
Cardiotoxicity	5 [12,13,14, 17, 24]	0.68	0%	Fixed-effect model	1.70	(0.79,3.68)	0.18
Liver and kidney function damage	4 [12, 17, 18, 24]	0.75	0%	Fixed-effect model	0.77	(0.40,1.50)	0.45
Fatigue	5 [13, 14, 17, 18, 24]	0.59	0%	Fixed-effect model	1.06	(0.60,1.87)	0.85
Leukopenia	6 [13, 14, 17,18,19, 24]	0.99	0%	Fixed-effect model	0.93	(0.61,1.42)	0.74
Thrombocytopenia	7 [12,13,14, 17,18,19, 24]	0.99	0%	Fixed-effect model	1.08	(0.71,1.64)	0.72

ISSN: 1477-7819